Dimitrios Iliopoulos

Dyania Health, Inc. develops a clinical research platform for pharmacies and hospitals. The company is based in Los Angeles, CA. The company was founded by Eirini Schlosser and Dimitrios Iliopoulos. Eirini Schlosser has been the CEO since incorporation.

Proteas Bioanalytics, Inc. is an innovative proteomics platform that advances molecular biology, biomarker development, and precision medicine. The private company is based in Torrance, CA and was founded by Spiros D. Garbis and Antigoni Manousopoulou. The company provides proteomics services and solutions to unmet needs in the field of neurodegenerative disorders, coronary artery disease, and cancer. Proteas Bioanalytics has collaborated with thought leaders and innovators in the medical field to develop novel blood biomarkers that are predictive of the progression from pre-malignant to active myeloma. Spiros D. Garbis has been the CEO since incorporation.

Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then.

Dyania Health, Inc. develops a clinical research platform for pharmacies and hospitals. The company is based in Los Angeles, CA. The company was founded by Eirini Schlosser and Dimitrios Iliopoulos. Eirini Schlosser has been the CEO since incorporation.

Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then.

Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then.